The messy morality of letting AI make life-and-death decisions
By Will Douglas Heaven,
MIT Technology Review
| 10. 13. 2022
GR Stocks on Unsplash
In a workshop in Rotterdam in the Netherlands, Philip Nitschke—“Dr. Death” or “the Elon Musk of assisted suicide” to some—is overseeing the last few rounds of testing on his new Sarco machine before shipping it to Switzerland, where he says its first user is waiting.
This is the third prototype that Nitschke’s nonprofit, Exit International, has 3D-printed and wired up. Number one has been exhibited in Germany and Poland. “Number two was a disaster,” he says. Now he’s ironed out the manufacturing errors and is ready to launch: “This is the one that will be used.”
A coffin-size pod with Star Trek stylings, the Sarco is the culmination of Nitschke’s 25-year campaign to “demedicalize death” through technology. Sealed inside the machine, a person who has chosen to die must answer three questions: Who are you? Where are you? And do you know what will happen when you press that button?
Here’s what will happen: The Sarco will fill with nitrogen gas. Its occupant will pass out in less than a minute and die by asphyxiation in around five. ...
Related Articles
By Harry Hunter, PET BioNews | 08.11.2025
The Parliamentary Office of Science and Technology has announced plans to publish a POSTnote and called for submissions on surrogacy law in the UK and internationally.
The current UK surrogacy laws, largely based on legislation from the 1980s, have been...
By Sayantani DasGupta, MedPage Today | 08.05.2025
It's just a jeans ad.
It's not that deep.
It's just social media outrage.
Should physicians care about the recent American Eagle "Sydney Sweeney Has Good Genes Jeans" controversy? What, if anything, does the provocative campaign have to...
By Zusha Elinson, The Wall Street Journal | 08.12.2025
BERKELEY, Calif.—Tsvi Benson-Tilsen, a mathematician, spent seven years researching how to keep an advanced form of artificial intelligence from destroying humanity before he concluded that stopping it wasn’t possible—at least anytime soon.
Now, he’s turned his considerable brainpower to promoting...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...